Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Company Overview - Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies [3] - The company is recognized for its lead compound, XPOVIO® (selinexor), which is an oral exportin 1 (XPO1) inhibitor approved in the U.S. for three oncology indications [3] - Karyopharm has received regulatory approvals for its products in various international markets, including Europe, the United Kingdom, and China [3] Upcoming Events - The senior management team of Karyopharm will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 11:30 a.m. ET in New York [1] - A live webcast of the event will be available on the company's investor website and can be replayed after the event [2] Product Pipeline - Karyopharm has a focused pipeline targeting multiple high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL) [3]